文献速递白血病

急性髓系白血病中白血病相关免疫表型的早期外周清除:随机试验的集中分析

Early peripheral clearance of leukemia-associated immunophenotypes in AML: centralized analysis of a randomized trial.
PubMed 文献 · Blood Adv · 2020-01-01

该随机试验比较标准诱导与高剂量诱导,在治疗3天后集中定量外周血白血病相关免疫表型(LAIP)阳性细胞的清除率(PBC),发现PBC可早期预测完全缓解(CR)及缓解后结局,且与诱导强度和遗传学风险相关。

要点

  • PBC以第1天与第4天LAIP+细胞绝对值的比值对数表示,可快速预测化疗反应。
  • CR患者中位PBC为2.3 log,显著高于化疗耐药患者的1.0 log(P < .0001)。
  • PBC >1.5 log者单疗程诱导后CR率达87.5%,而≤1.5 log者仅43.6%(P < .0001)。

核心结论

  • PBC分析可极早期预测AML结局,并与治疗强度和疾病亚群相关,可能支持个体化治疗研究。

研究设计与样本

  • 随机试验(ClinicalTrials.gov #NCT00495287)比较标准诱导与高剂量诱导,共178例患者,151例(84.8%)可评估。

主要发现

  • CR患者中位PBC为2.3 log,化疗耐药患者为1.0 log(P < .0001)。
  • PBC < 1.0预测最差结局,CR率仅28%。
  • 以1.5 log为最准确CR预测界值,PBC >1.5组(n=96)CR率87.5%,PBC ≤1.5组(n=55)CR率43.6%(P < .0001)。
  • 高剂量诱导组CR率和PBChigh率增加(P = .04),且与遗传/细胞遗传学风险强相关。
  • 多变量分析中PBC对CR、复发风险和生存保持显著预测力。

关键数值与推荐

  • PBC以第1天和第4天LAIP+细胞绝对值的比值对数表示。
  • PBC < 1.0预测最差结局(CR率28%)。
  • 1.5 log为预测CR最准确界值。

临床怎么用

  • 治疗3天后可集中检测LAIP+细胞清除率,辅助早期识别高危患者并调整治疗策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Although genetics is a relevant risk factor in acute myeloid leukemia (AML), it can be minimally informative and/or not readily available for the early identification of patients at risk for treatment failure. In a randomized trial comparing standard vs high-dose induction (ClinicalTrials.gov #NCT00495287), we studied early peripheral blast cell clearance (PBC) as a rapid predictive assay of chemotherapy response to determine whether it correlates with the achievement of complete remission (CR), as well as postremission outcome, according to induction intensity. Individual leukemia-associated immunophenotypes (LAIPs) identified pretherapy by flow cytometry were validated and quantified centrally after 3 days of treatment, expressing PBC on a logarithmic scale as the ratio of absolute LAIP+ cells on day 1 and day 4. Of 178 patients, 151 (84.8%) were evaluable. Patients in CR exhibited significantly higher median PBC (2.3 log) compared with chemoresistant patients (1.0 log; P < .0001). PBC < 1.0 predicted the worst outcome (CR, 28%). With 1.5 log established as the most accurate cutoff predicting CR, 87.5% of patients with PBC >1.5 (PBChigh, n = 96) and 43.6% of patients with PBC ≤1.5 (PBClow, n = 55) achieved CR after single-course induction (P < .0001). CR and PBChigh rates were increased in patients randomized to the high-dose induction arm (P = .04) and correlated strongly with genetic/cytogenetic risk. In multivariate analysis, PBC retained significant predictive power for CR, relapse risk, and survival. Thus, PBC analysis can provide a very early prediction of outcome, correlates with treatment intensity and disease subset, and may support studies of customized AML therapy.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Gianfaldoni G, Mannelli F, Intermesoli T, et al. Early peripheral clearance of leukemia-associated immunophenotypes in AML: centralized analysis of a randomized trial. Blood Adv. 2020. PMID: 31978214. doi:10.1182/bloodadvances.2019000406

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。